Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Core Insights - Verrica Pharmaceuticals Inc. is set to present its investigational therapy VP-315 for basal cell carcinoma at the SITC 40th Annual Meeting in November 2025 [1][3][4] Presentation Details - The oral presentation will occur during the Rapid Oral Abstract Session on November 5, 2025, featuring an exploratory analysis of a phase 2 multicenter study on local immune activation post VP-315 treatment [3][4] - The abstract for the presentation will be available on the SITC website on November 4, 2025 [2] About VP-315 - VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy designed to induce immunogenic cell death in tumors, providing a non-surgical treatment option for skin cancer patients [5] - The therapy is based on research into "host defense peptides" and aims to target non-metastatic melanoma and non-metastatic Merkel cell carcinoma, with a focus on basal cell and squamous cell carcinomas [5] About Verrica Pharmaceuticals Inc. - Verrica is a dermatology therapeutics company that has developed YCANTH (VP-102), the first FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million people in the U.S. [6][7] - The company has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers [7]